Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rivastigmine
Drug ID BADD_D01955
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status approved; investigational
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D03822
MeSH ID D000068836
PubChem ID 77991
TTD Drug ID D0WY5Q
NDC Product Code 16714-117; 70710-1198; 72855-101; 0781-7304; 65372-1153; 82245-0107; 51956-0001; 51956-0002; 51991-898; 65162-826; 72855-102; 49706-1825; 0078-0503; 63629-2065; 65162-749; 65162-825; 0378-9072; 0781-7309; 12651-118; 64552-4021; 65015-819; 0078-0501; 63629-8846; 0378-9071; 70710-1196; 16714-115; 63629-2066; 50379-0014; 65862-982; 72855-100; 51956-0003; 51991-897; 51991-899; 0781-7313; 63629-2064; 0378-9070; 0078-0502; 16714-116; 63629-8807; 70710-1197
UNII PKI06M3IW0
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C14H22N2O2
CAS Registry Number 123441-03-2
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Decreased appetite14.03.01.005; 08.01.09.0280.006341%
Psychiatric symptom19.01.02.0010.000542%Not Available
Parkinson's disease17.01.05.0100.005691%Not Available
Disease progression08.01.03.038--
Drug intolerance08.06.01.0130.007208%Not Available
Psychotic disorder19.03.01.0020.001626%
Renal impairment20.01.03.010--Not Available
Increased bronchial secretion22.12.01.0020.000542%Not Available
Application site hypersensitivity08.02.01.013; 12.07.01.014; 10.01.03.0090.001355%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.001084%Not Available
Skin haemorrhage24.07.01.103; 23.06.07.001--Not Available
Dementia with Lewy bodies19.20.02.003; 17.03.01.0040.001084%Not Available
Hepatic cancer16.07.02.004; 09.04.02.008--Not Available
Multiple organ dysfunction syndrome08.01.03.0570.001626%
Anal incontinence17.05.01.021; 07.01.06.0290.000542%
Concomitant disease aggravated08.01.03.0630.000813%Not Available
Obstruction gastric07.13.04.0020.000542%
Oesophageal dilatation07.11.02.0050.000542%Not Available
Senile dementia17.03.01.008; 19.20.02.0090.000813%Not Available
Slow response to stimuli17.02.05.0630.000813%Not Available
Terminal state08.01.03.0790.000813%Not Available
Neurodegenerative disorder17.02.10.0240.001084%Not Available
Gastrointestinal oedema07.11.01.0120.000542%Not Available
Apparent death08.01.03.0620.001084%Not Available
Hyporesponsive to stimuli17.02.05.0570.000542%Not Available
Spinal pain15.02.01.008; 08.01.08.030; 17.10.01.0200.000542%Not Available
Application site acne12.07.01.047; 08.02.01.047; 23.02.01.0090.001843%Not Available
Behaviour disorder19.01.01.0050.001192%Not Available
Gait inability17.02.05.069; 08.01.02.0110.003523%Not Available
Illness08.01.03.0910.002276%Not Available
The 10th Page    First    Pre   10 11    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene